|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia.
|
19691103 |
2009 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutively activated mutants of the non-receptor tyrosine kinases (TK) ABL1 (Abelson murine leukemia viral (v-abl) homolog (1) protein) and JAK2 (JAnus Kinase 2 or Just Another Kinase 2) play a central role in the pathogenesis of clinically and morphologically distinct chronic myeloproliferative disorders but are also found in some cases of de novo acute leukemia and lymphoma.
|
18528425 |
2008 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.
|
17851549 |
2008 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The only patient with non-Down's syndrome-associated leukaemia but with a JAK2 mutation had an isochromosome 21q.
|
18805579 |
2008 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01).
|
17229652 |
2007 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pre-TCR signaling synergizes with TEL-JAK2 to transform immature thymocytes and initiate leukemogenesis as shown by (1) the delayed leukemia onset in Rag2-, CD3epsilon- and pTalpha-deficient mice, (2) the occurrence of recurrent chromosomal alterations in pre-TCR-deficient leukemia, and (3) the correction of delayed leukemia onset in Rag2-deficient TEL-JAK2 mice by an H-Y TCRalphabeta transgene that mimics pre-TCR signaling.
|
17192390 |
2007 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Moreover, JAK2 V617F mutations in CBF leukemias were associated with an aggressive clinical course with 80% of the patients relapsing.
|
17229652 |
2007 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
|
16557239 |
2006 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aberrant activation of the JAK-STAT pathway has been implicated in tumor formation; for example, constitutive activation of JAK2 kinase or the enforced expression of STAT5 induces leukemia in mice.
|
15578097 |
2004 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fusion of the TEL gene on 12p13 to the JAK2 tyrosine kinase gene on 9p24 has been found in human leukemia.
|
11278610 |
2001 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
TEL-JAK2 founder mice and their transgenic progeny developed fatal leukemia at 4 to 22 weeks of age.
|
10845925 |
2000 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently reported the involvement of ETV6-JAK2 fusion genes in the development of leukemia of both lymphoid and myeloid origin.
|
10449913 |
1999 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that all human TEL/JAK2 fusion variants are oncoproteins in vitro that strongly activate STAT 5, and cause lethal myelo- and lymphoproliferative syndromes in murine bone marrow transplant models of leukemia.
|
9736611 |
1998 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
|
9360930 |
1997 |